Last reviewed · How we verify

Ibuprofen group

University of Salamanca · FDA-approved active Small molecule

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins, thereby decreasing inflammation, pain, and fever.

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Fever reduction, Inflammatory conditions (e.g., rheumatoid arthritis, osteoarthritis).

At a glance

Generic nameIbuprofen group
Also known asMotrin, Brufen® syrup, Samil pharm. Co., Ltd., Active drug, Advil, Brufen
SponsorUniversity of Salamanca
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCOX-1, COX-2
ModalitySmall molecule
Therapeutic areaPain Management, Inflammation, Fever
PhaseFDA-approved

Mechanism of action

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively blocks COX-1 and COX-2 enzymes, which catalyze prostaglandin synthesis. By reducing prostaglandin levels, it suppresses inflammatory responses, alleviates pain signaling, and lowers body temperature. This mechanism makes it effective for mild to moderate pain, fever, and inflammatory conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: